Skip to main content

Table 1 Patient demographic and clinical data

From: Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer

Variable Value
Age (n = 121)* 69.5 ± 0.7
NAAD 56/83 (67.5%)
Time of hormonal treatment (mon; n = 52)* 9.3 ± 1.1
Gleason Score (n = 132) 6 (5 - 10)
Pre-PSA (ng/mL)* 9.5 ± 0.6
Unilateral disease 65/117 (55.6%)
IMRT Boost 31/130 (23.9%)
Tumor stage  
   T1c 100/130 (76.9%)
   T2 5/130 (3.9%)
   T2a 13/130 (10.0%)
   T2b 4/130 (3.1%)
   T2c 2/130 (1.5%)
   T3 3/130 (2.3%)
   T3a 2/130 (1.5%)
   T3b 1/130 (0.8%)
  1. Abbreviation: NAAD = Neoadjuvant androgen deprivation therapy; PSA = Prostate specific antigen; IMRT = intensity modulated radiation therapy
  2. * mean ± SEM
  3. † median (range in parentheses)